Pioglitazone
- Generic Name
- Pioglitazone
- Brand Names
- Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N2O3S
- CAS Number
- 111025-46-8
- Unique Ingredient Identifier
- X4OV71U42S
- Background
Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medicatio...
- Indication
Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.
- Associated Conditions
- Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Safety Study of Pioglitazone Compared To Glyburide on Liver Function
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 2120
- Registration Number
- NCT00494312
The Effect of Pioglitazone on Neointima Volume and Inflammatory Markers
- Conditions
- Interventions
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT00494559
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
Pioglitazone on Cardiac Function and Large Arteries (PICCOLA Study)
- First Posted Date
- 2007-06-12
- Last Posted Date
- 2016-08-09
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 24
- Registration Number
- NCT00485056
- Locations
- 🇬🇧
International Centre for Circulatory Health, London, United Kingdom
Study of Rivoglitazone in Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1912
- Registration Number
- NCT00484198
Comparison Between Pioglitazone and SES With type2 DM
- Conditions
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2007-06-05
- Lead Sponsor
- Showa University
- Target Recruit Count
- 38
- Registration Number
- NCT00482183
Effects of Pioglitazone in Type 2 Diabetes Mellitus and Coronary Heart Disease
- Conditions
- Interventions
- First Posted Date
- 2007-05-30
- Last Posted Date
- 2015-04-01
- Target Recruit Count
- 92
- Registration Number
- NCT00479986
- Locations
- 🇩🇪
Dr. Michael Morcos, Heidelberg, Germany
🇩🇪IKFE, Mainz, Germany
The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients
- Conditions
- First Posted Date
- 2007-04-13
- Last Posted Date
- 2007-04-13
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 20
- Registration Number
- NCT00459940
- Locations
- 🇩🇰
Medical Department M, The Medical Research Laboratories, Aarhus University Hospital, Aarhus C, Denmark
Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance
- Conditions
- Interventions
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 28
- Registration Number
- NCT00443755
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Pioglitazone to Treat Fatty Liver in People With HIV Infection
- Conditions
- First Posted Date
- 2007-02-28
- Last Posted Date
- 2010-02-19
- Target Recruit Count
- 100
- Registration Number
- NCT00441272
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Medication in Early Diabetes (MED) Study
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- Menzies School of Health Research
- Registration Number
- NCT00437970
- Locations
- 🇦🇺
Menzies School of Health Research, Darwin, Northern Territory, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.